Literature summary for 3.2.1.102 extracted from

Kobayashi, T.; Liu, D.; Ogawa, H.; Miwa, Y.; Nagasaka, T.; Maruyama, S.; Li, Y.T.; Onishi, A.; Iwamoto, M.; Kuzuya, T.; Kadomatsu, K.; Uchida, K.; Nakao, A.
Removal of blood group A/B antigen in organs by ex vivo and in vivo administration of endo-beta-galactosidase (ABase) for ABO-incompatible transplantation (2009), Transpl. Immunol., 20, 132-138.

Search for more literature for 3.2.1.102

Application

Application	Comment	Organism
medicine	for ABO-incomatible transplantation	Clostridium perfringens

Cloned(Commentary)

Cloned (Comment)	Organism
expression in Escherichia coli BL-21	Clostridium perfringens

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining
soluble	-	Clostridium perfringens	-	-

Organism

Organism	UniProt	Comment	Textmining
Clostridium perfringens	-	-	-

Purification (Commentary)

Purification (Comment)	Organism
nickel-nitrilotriacetic acid column	Clostridium perfringens

Specific Activity [micromol/min/mg]

Specific Activity Minimum [µmol/min/mg]	Specific Activity Maximum [µmol/min/mg]	Comment	Organism
1500	-	still acitve after 500-fold dilution of the enzyme	Clostridium perfringens

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
Galalpha(1-3)[Fucalpha(1-2)]Galbeta(1-4)GlcNAcbeta-R + H2O	analog of blood group B antigen, digested more effciently than the blood group A analog	Clostridium perfringens	Galalpha(1-3)[Fucalpha(1-2)]Gal + GlcNAcbeta-R	-	?
GalNAcalpha(1-3)[Fucalpha(1-2)]Galbeta(1-4)GlcNAcbeta-R + H2O	analog of blood group A antigen	Clostridium perfringens	GalNAcalpha(1-3)[Fucalpha(1-2)]Gal + GlcNAcbeta-R	-	?

Synonyms

Synonyms	Comment	Organism
ABase	-	Clostridium perfringens
endo-beta-galactosidase	-	Clostridium perfringens

Temperature Stability [°C]

Temperature Stability Minimum [°C]	Temperature Stability Maximum [°C]	Comment	Organism
4	-	stable at 4°C	Clostridium perfringens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)